Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
ABSI(NASDAQ:ABSI) Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs
Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
ABSIWorld-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia.
World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia.
Absci to Participate in Upcoming Investor Conferences
ABSIVANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the following upcoming investor conferences:
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
ABSIStrengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
ABSIBARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall’s selection of a second target aimed at dermatological indications.
Assessing Absci: Insights From 6 Financial Analysts
ABSINeedham Reiterates Buy on Absci, Maintains $9 Price Target
ABSIAbsci Doses First Participants In Phase 1 Clinical Trial Of ABS-101
ABSIAbsci Q1 EPS $(0.21) Beats $(0.22) Estimate, Sales $1.20M Beat $1.07M Estimate
ABSIKeybanc Maintains Overweight on Absci, Raises Price Target to $9
ABSINvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
ABSIFDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
ABSIHealth Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements
ABSISeveral stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing requirements.
Absci Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
ABSINeedham Reiterates Buy on Absci, Maintains $9 Price Target
ABSICathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
ABSICathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.
Guggenheim Reiterates Buy on Absci, Maintains $10 Price Target
ABSIAbsci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
ABSIA Glimpse Into The Expert Outlook On Absci Through 7 Analysts
ABSINeedham Reiterates Buy on Absci, Maintains $9 Price Target
ABSIHC Wainwright & Co. Reiterates Buy on Absci, Maintains $7 Price Target
ABSIWhy StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
ABSI12 Health Care Stocks Moving In Tuesday's After-Market Session
ABSIAbsci Q4 2024 GAAP EPS $(0.25) Misses $(0.23) Estimate, Sales $665.000K Miss $1.778M Estimate
ABSIEarnings Scheduled For March 18, 2025
ABSICathie Wood-Led Ark Invest Offloads Roblox, Roku, UiPath As Markets Take A Dip
ABSIArk Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.
HC Wainwright & Co. Reiterates Buy on Absci, Maintains $7 Price Target
ABSIAbsci Corporation And Owkin Announced A Partnership Bringing Together Two Leading Ai Platforms To Rapidly Discover And Design Novel Therapeutics For Patients
ABSIAbsci And Twist Bioscience Collaborate To Design Novel Antibody Using Generative AI
ABSI